Chinese Regulators Accept Fosun Pharma Unit's Registration Application for Hemorrhage Treatment
© MT Newswires 2022
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
|
|
|
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
|
|
| |
|
Sales 2022 |
43 494 M
6 455 M
6 455 M
|
Net income 2022 |
5 095 M
756 M
756 M
|
Net Debt 2022 |
16 460 M
2 443 M
2 443 M
|
P/E ratio 2022 |
22,2x |
Yield 2022 |
1,29% |
|
Capitalization |
103 B
15 195 M
15 300 M
|
EV / Sales 2022 |
2,75x |
EV / Sales 2023 |
2,42x |
Nbr of Employees |
36 279 |
Free-Float |
58,6% |
|
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. |
|
Duration :
Period :
|
 |
|
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
| Short Term | Mid-Term | Long Term | Trends | Bearish | Neutral | Bearish |
Income Statement Evolution
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
11 |
Last Close Price |
43,47 CNY |
Average target price |
55,27 CNY |
Spread / Average Target |
27,1% |
|